It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HLNCF’s FA Score shows that 1 FA rating(s) are green whileSTEK’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HLNCF’s TA Score shows that 6 TA indicator(s) are bullish while STEK’s TA Score has 4 bullish TA indicator(s).
HLNCF (@Pharmaceuticals: Other) experienced а +3.23% price change this week, while STEK (@Pharmaceuticals: Other) price change was -7.55% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.61%. For the same industry, the average monthly price growth was +1.68%, and the average quarterly price growth was -9.09%.
STEK is expected to report earnings on Apr 17, 2023.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
HLNCF | STEK | HLNCF / STEK | |
Capitalization | 39.9B | 2.98M | 1,339,825% |
EBITDA | 2.06B | -4.36M | -47,146% |
Gain YTD | 17.073 | 50.769 | 34% |
P/E Ratio | 27.25 | 1.05 | 2,606% |
Revenue | 11.2B | 4.54M | 246,914% |
Total Cash | 606M | 343K | 176,676% |
Total Debt | 10.4B | 1.15M | 903,562% |
STEK | ||
---|---|---|
OUTLOOK RATING 1..100 | 90 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | |
PROFIT vs RISK RATING 1..100 | 99 | |
SMR RATING 1..100 | 97 | |
PRICE GROWTH RATING 1..100 | 35 | |
P/E GROWTH RATING 1..100 | 93 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
HLNCF | STEK | |
---|---|---|
RSI ODDS (%) | 2 days ago83% | 2 days ago77% |
Stochastic ODDS (%) | 2 days ago68% | 2 days ago84% |
Momentum ODDS (%) | 2 days ago52% | 2 days ago80% |
MACD ODDS (%) | 2 days ago69% | 2 days ago84% |
TrendWeek ODDS (%) | 2 days ago61% | 2 days ago85% |
TrendMonth ODDS (%) | 2 days ago63% | 2 days ago81% |
Advances ODDS (%) | 16 days ago63% | 24 days ago80% |
Declines ODDS (%) | 6 days ago51% | 6 days ago90% |
BollingerBands ODDS (%) | 2 days ago53% | 2 days ago86% |
Aroon ODDS (%) | 2 days ago75% | N/A |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
CANC | 25.56 | 0.17 | +0.69% |
Tema Oncology ETF | |||
IGLB | 50.88 | 0.02 | +0.04% |
iShares 10+ Year Invmt Grd Corp Bd ETF | |||
CSM | 68.07 | -0.25 | -0.37% |
ProShares Large Cap Core Plus | |||
HSCZ | 32.38 | -0.15 | -0.45% |
iShares Currency Hdgd MSCI EAFE SmCp ETF | |||
WEIX | 27.26 | -0.33 | -1.20% |
Dynamic Short Short-Term Volatil Fut ETF |
A.I.dvisor indicates that over the last year, HLNCF has been loosely correlated with HLN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HLNCF jumps, then HLN could also see price increases.
Ticker / NAME | Correlation To HLNCF | 1D Price Change % | ||
---|---|---|---|---|
HLNCF | 100% | N/A | ||
HLN - HLNCF | 49% Loosely correlated | +1.95% | ||
SGIOF - HLNCF | 21% Poorly correlated | N/A | ||
STEK - HLNCF | 11% Poorly correlated | -1.80% | ||
EAPIF - HLNCF | 11% Poorly correlated | -10.63% | ||
ZTS - HLNCF | 10% Poorly correlated | -2.86% | ||
More |
A.I.dvisor tells us that STEK and CNADF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that STEK and CNADF's prices will move in lockstep.
Ticker / NAME | Correlation To STEK | 1D Price Change % | ||
---|---|---|---|---|
STEK | 100% | -1.80% | ||
CNADF - STEK | 25% Poorly correlated | N/A | ||
BFRI - STEK | 12% Poorly correlated | -4.40% | ||
HLNCF - STEK | 11% Poorly correlated | N/A | ||
PLSH - STEK | 8% Poorly correlated | -32.22% | ||
EAPIF - STEK | 6% Poorly correlated | -10.63% | ||
More |